219 US companies filed quarterly results with the SEC (8-K Item 2.02). We read 70 and called the likely one-week price move. Calls are graded in the open.
The company reported a net loss of $45,000 in Q3 2026, compared to a net income of $772,000 in Q3 2025, and a significant decrease in gross margin due to volume discounts and higher inventory reserves. The recent rights offering also resulted in a 32.1% increase in revenues, but the net loss and decreased gross margin may negatively impact the stock price.
OUR ANALYSIS → VIEW 8-K →The company has reported its Q3 2026 financial results and provided a business outlook, but the filing does not contain any quantified surprises or significant updates that would impact the stock price beyond routine earnings news.
OUR ANALYSIS → VIEW 8-K →Kodiak Sciences raised $69 million through an at-the-market equity offering, which will lead to dilution, and reported a net loss of $66.2 million for the third quarter of 2026, with R&D expenses increasing to $58.3 million.
OUR ANALYSIS → VIEW 8-K →SpyGlass Pharma reported strong third-quarter financial results, announced the completion of first implantations in the first-in-human study of the Bimatoprost-Drug Ring System, and provided corporate updates, including the acquisition of Advanced Vision Science, Inc. and four-year efficacy and safety follow-up data of the BIM-IOL System, showing a 37% reduction in mean intraocular pressure and 86
OUR ANALYSIS → VIEW 8-K →The company announced the initiation of GLP toxicology studies for its lead candidate AKTX-101 and new preclinical findings demonstrating activity in models resistant to existing ADC therapies, but noted that the planned Phase 1 clinical trial in mid-2027 is subject to obtaining additional financing, implying a potential need for dilution.
OUR ANALYSIS → VIEW 8-K →The company has changed its auditor from PKF O'Connor Davies, LLP to Macias Gini & O'Connell LLP, and there were no disagreements with the former auditor on accounting principles or practices, but the former auditor did note a material weakness in the company's internal control over financial reporting, specifically regarding the company's ability to continue as a going concern.
OUR ANALYSIS → VIEW 8-K →The company's Q3 2026 results show improved financials and operational performance, but the ATM program share placement may lead to dilution, and the announcement lacks a significant quantified surprise to drive a substantial price move.
OUR ANALYSIS → VIEW 8-K →Planet 13 reported a Q3 revenue of $23.1 million, a net loss of $6.4 million, and an Adjusted EBITDA loss of $0.2 million, with a proposed merger with Vireo Growth Inc. pending a stockholder vote on December 10, 2026. The company's financials show improvement in revenue and Adjusted EBITDA compared to the prior year, but the market reaction will depend on the merger's outcome and the company's fut
OUR ANALYSIS → VIEW 8-K →Verrica Pharmaceuticals reported record Q3 revenue of $6.9 million, with YCANTH net product revenue up 57.9% year-over-year, and announced the completion of enrollment in the first pivotal trial for common warts, with topline data expected in Q1 2027. The company also unlocked access to $27.5 million in non-dilutive growth capital, extending its cash runway through data readouts for both common wa
OUR ANALYSIS → VIEW 8-K →Trio-Tech International reports 33% sequential and 29% year-over-year revenue growth for the first quarter of fiscal 2027, driven by strong demand for AI GPU burn-in boards and higher testing volumes for EV, data center, and AI-related semiconductor applications, with consolidated gross profit rising 59% and diluted EPS reaching $0.07.
OUR ANALYSIS → VIEW 8-K →Presurance Holdings reported a significant improvement in its combined ratio and a reduction in net loss, but the stock's movement will depend on how these results compare to market expectations. The company's book value per share has decreased to $6.45 from $14.49 in the prior year period, which may be a concern for investors.
OUR ANALYSIS → VIEW 8-K →This 8-K filing is for an Investor Day announcement, which is a routine event and does not contain any quantified surprises, and the information disclosed is not likely to significantly impact the stock price.
OUR ANALYSIS → VIEW 8-K →Neonode reported a 24.4% increase in revenues from continuing operations and a 13.2% decrease in operating expenses, but still incurred a loss from continuing operations of $1.1 million, or $0.07 per share, due to the absence of a one-time gain from patent assignment recognized in the prior year. The company's cash balance decreased to $20.2 million as of September 30, 2026, from $25.8 million as
OUR ANALYSIS → VIEW 8-K →LiveOne reports Q2 Fiscal 2027 revenue of $18.0M and adjusted EBITDA of $(0.7)M, with H1 Fiscal 2027 revenue of $37.3M and adjusted EBITDA of $3.6M, and revises Fiscal 2027 guidance to $70-$75M in revenue and $10M+ in adjusted EBITDA
OUR ANALYSIS → VIEW 8-K →The company reported a net loss of $17.5 million and adjusted EBITDA of -$3.2 million, but showed revenue growth of 31% from the previous quarter, and has secured approximately 8 MW of critical IT capacity, with 1.5 MW live and supporting $22 million of contracted ARR. However, the company also closed a private placement of approximately 4.26 million shares of common stock, which may lead to dilut
OUR ANALYSIS → VIEW 8-K →Century Therapeutics reported a cash position of $174.1 million, which is expected to support operations into 1Q 2029, and announced progress on its two potentially transformational programs, CNTY-813 and CNTY-308, with IND submission and clinical trial initiation planned for 4Q 2026 and 2026, respectively.
OUR ANALYSIS → VIEW 8-K →CaliberCos Inc. reported third quarter financial results with Platform Adjusted EBITDA of $0.1 million, compared to a loss of $0.7 million in the same period last year, and revised its 2026 revenue guidance downward to $15.0-17.0 million due to tighter credit conditions, but reaffirmed its Platform Adjusted EBITDA profitability guidance
OUR ANALYSIS → VIEW 8-K →Artesian Resources Corporation reported a 3.0% decrease in net income for the third quarter and a 3.1% increase in net income for the nine months ended September 30, 2026, with revenues increasing 4.8% and 6.4%, respectively, but the earnings per share decrease in the third quarter may have a negative impact on the stock price
OUR ANALYSIS → VIEW 8-K →The company reported a net loss of $0.1 million or $0.02 per share for Q3 2026, compared to net income of $0.7 million or $0.08 per share for the same period in 2025, with revenues increasing $1.1 million to $13.9 million, primarily due to an increase in multifamily properties revenue, but net operating loss increased approximately $1.0 million due to higher operating expenses from lease-up proper
OUR ANALYSIS → VIEW 8-K →The company reported its first pre-commercial product revenue from agenT-797 and announced advancements in its randomized ARDS trial, with U.S. dosing expected before year-end, but the update lacks specific quantified surprises on earnings or guidance beats.
OUR ANALYSIS → VIEW 8-K →Tecogen reported a smaller net loss of $1.59 million for Q3 2026 compared to $2.13 million in Q3 2025, with revenue increasing 9.6% year-over-year, and the company's backlog is over $8 million, driven by demand for its products in large commercial and industrial facilities. The CEO also highlighted an innovation that allows customers to use the company's technology as a retrofit to existing chille
OUR ANALYSIS → VIEW 8-K →CuriosityStream reported strong Q3 2026 results with 13% revenue growth and 67% Adjusted EBITDA growth, and raised its full-year 2026 revenue and adjusted EBITDA guidance. The company also declared a quarterly cash dividend of $0.085 per share.
OUR ANALYSIS → VIEW 8-K →Vivani Medical announced positive top-line results from a Phase 1 trial of its semaglutide implant, NPM-139, showing no treatment-related adverse events and comparable weight loss to Wegovy, a weekly semaglutide injection. The company plans to advance NPM-139 to a Phase 2 trial in 2027.
OUR ANALYSIS → VIEW 8-K →Vylor Inc. reaffirms full-year guidance and announces a new $3 billion share repurchase program, demonstrating confidence in its 2029 Financial Framework, but the filing lacks a significant quantified surprise to drive a substantial price move.
OUR ANALYSIS → VIEW 8-K →Mexco Energy Corporation reported a 67% increase in net income for the six months ended September 30, 2026, and a 21% increase in operating revenues, driven by a 43% increase in average oil price. The company also announced plans to participate in the drilling of 55 horizontal wells and the completion of 20 horizontal wells at an estimated aggregate cost of approximately $1.8 million during the fi
OUR ANALYSIS → VIEW 8-K →ROC reported record quarterly revenue of $8.0 million, up 50% year-over-year, and achieved quarterly profitability, driven by strong software licensing performance and significant federal contract wins, including a $64.3 million Department of Justice digital evidence contract award
OUR ANALYSIS → VIEW 8-K →The company has issued an earnings presentation and press release announcing its financial and operating results for the quarter ended September 30, 2026, but the filing does not contain any quantified surprises or significant updates that would impact the stock price.
OUR ANALYSIS → VIEW 8-K →The company is exploring strategic alternatives, including a potential sale or merger, and has retained a financial advisor, indicating potential significant changes, but no specific quantified surprises are disclosed in the filing.
OUR ANALYSIS → VIEW 8-K →Vista Gold Corp has announced its third quarter 2026 financial results and a confirmed takeover by Artemis Gold Inc at a premium, with shareholders to receive 0.0966 of an Artemis common share for each Vista share, valuing the company at a significant premium to its current market price. The deal is subject to regulatory approvals but represents a substantial value realization for Vista shareholde
OUR ANALYSIS → VIEW 8-K →Nocopi Technologies reported a significant increase in revenue and net income for the third quarter, driven by the acquisition of Polymeric and an early license renewal, with total revenues increasing 763% to $3.329 million and net income of $1.397 million, or $0.12 per share.
OUR ANALYSIS → VIEW 8-K →The company reported its Q3 financial results, which may have been already priced in by the market, and there are no quantified surprises in the filing. The forward-looking statements and risk factors discussed are typical for the industry and do not indicate any significant changes to the company's outlook.
OUR ANALYSIS → VIEW 8-K →The company's third-quarter revenue increased 40% sequentially, gross margin improved to 65.9%, and net loss narrowed 74% sequentially, with a net cash position of approximately $14.9 million, which is approximately 12 times its market capitalization.
OUR ANALYSIS → VIEW 8-K →Motorsport Games Inc. reported a 21.8% increase in revenue for Q3 2026 and a 52.3% increase for the nine months ended September 30, 2026, with expanding gross margin and seven consecutive quarters of profitability, but no specific guidance or surprises were disclosed beyond the earnings report.
OUR ANALYSIS → VIEW 8-K →The company reported a narrower net loss of $0.4 million and a 25% gross margin from its fire safety business, with $454,000 in product revenue, but the filing lacks a significant quantified surprise to drive a substantial price move.
OUR ANALYSIS → VIEW 8-K →The company reported its Q3 2026 results, providing both GAAP and non-GAAP financial measures, but the filing does not disclose any quantified surprises such as earnings or guidance beats.
OUR ANALYSIS → VIEW 8-K →Spruce Power reported a net income of $6.0 million and operating EBITDA of $27.0 million for the third quarter, with SG&A expenses down 23% year-over-year, and the company reduced its debt principal by $21.9 million during the quarter. The results indicate a positive trend in the company's financial performance, driven by cost discipline and operational execution.
OUR ANALYSIS → VIEW 8-K →InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System, which is expected to approximately double the U.S. addressable market, and reported $2.2 million in revenue for the third quarter, a 9% increase year over year internationally, but an 11.1% decrease overall compared to the same period last year.
OUR ANALYSIS → VIEW 8-K →Aeluma's Q1 fiscal 2027 results showed a net loss of $3.8 million and revenue of $0.6 million, with cash and cash equivalents totaling $53.9 million, and the company is progressing with technology development and customer engagements in the AI Datacom market, including a purchase agreement with Aixtron for manufacturing expansion and potential funding from the U.S. Department of Commerce CHIPS R&D
OUR ANALYSIS → VIEW 8-K →Sutro Biopharma reported a strong balance sheet with $142.2 million in cash and provided updates on its pipeline, including the advancement of STRO-004 and STRO-006, but no quantified surprises were disclosed in the filing.
OUR ANALYSIS → VIEW 8-K →The company's cash and cash equivalents of $107.9 million are expected to fund operations into the second half of 2029, and they are advancing SP001 toward a Phase 2 study in IgG4-related disease, but the recent $105 million non-recourse, non-dilutive milestone and royalty financing does not imply dilution and the overall update seems to be in line with expectations.
OUR ANALYSIS → VIEW 8-K →Laird Superfood reported a 225% increase in third-quarter revenue to $42.0 million and net income of $1.7 million, driven by the acquisition of Navitas and Terrasoul, but gross margin compression due to inflationary costs and lower margins from Terrasoul. The company has $17.3 million in cash and no debt, positioning it for continued growth.
OUR ANALYSIS → VIEW 8-K →The company announced completion of enrollment in the first two cohorts of its Phase 2 early-onset fetal growth restriction trial and surpassed the 200-participant enrollment threshold for the ReMEDy2 Phase 2/3 acute ischemic stroke trial, but no quantified financial surprises were disclosed.
OUR ANALYSIS → VIEW 8-K →Nektar Therapeutics reported a net loss of $55.7 million or $1.63 basic and diluted net loss per share for the third quarter of 2026, with revenue of $9.4 million and total operating costs and expenses of $67.2 million, and the company has $952.9 million in cash and investments in marketable securities as of September 30, 2026. The company initiated all three global ZENITH AD registrational trials
OUR ANALYSIS → VIEW 8-K →The company reported a net loss of $0.7 million or $0.04 per share for Q3 2026, compared to a net income of $0.1 million or $0.01 per share for the same period in 2025, and total occupancy was 82% at September 30, 2026. The company also announced the purchase of four multifamily properties in exchange for the settlement of notes receivable and a cash payment of $12.0 million.
OUR ANALYSIS → VIEW 8-K →The company reported a net income of $0.9 million or $0.22 per diluted share for the quarter ended September 30, 2026, which is a slight decrease from the same period in 2025 due to a decrease in interest income. The earnings per share is lower than the previous year, but there is no significant surprise or quantified beat in the announcement.
OUR ANALYSIS → VIEW 8-K →The company reported a 6% increase in third-quarter revenue to $7.6 million and a 14% increase in nine-month revenue to $23.1 million, driven by growth in Direct Patient Services, but also reported a net loss due to higher operating costs and expenses.
OUR ANALYSIS → VIEW 8-K →Ideal Power Inc. reported third quarter 2026 financial results, highlighting expanded customer engagements and progress in its B-TRAN commercial strategy, including collaborations and new customer evaluations, but no quantified surprises or significant financial metrics were disclosed.
OUR ANALYSIS → VIEW 8-K →Digi International Inc. reported fourth fiscal quarter and full year fiscal 2026 results, showing revenue growth and increased net income, but no specific quantified surprises or guidance beats are mentioned in the filing.
OUR ANALYSIS → VIEW 8-K →Boost Run Inc. reported strong Q3 2026 results with $2.7 billion in total contract value, 496% year-over-year revenue growth, and $65.6 million in operating cash flow, driven by its position in the AI infrastructure market.
OUR ANALYSIS → VIEW 8-K →The company reported a net loss of $7.1 million for the quarter, primarily due to a non-cash impairment charge of $9.2 million, and a decline in net revenue of 5.4% to $26.7 million. Without the impairment charge, the net loss would have been approximately $240 thousand or $0.03 per share.
OUR ANALYSIS → VIEW 8-K →M-tron Industries reported a 66.4% increase in net income to $3.0 million for the third quarter, beating expectations, with revenue growth driven by strong demand in aerospace and defense markets.
OUR ANALYSIS → VIEW 8-K →Star Equity Holdings reported a 12.4% revenue increase and a net loss of $2.2 million, with adjusted EBITDA of $1.5 million, and announced plans to monetize real estate assets, but the results are largely in line with expectations and do not contain significant quantified surprises.
OUR ANALYSIS → VIEW 8-K →DeFi Development Corp. reported strong Q3 2026 results with NAV per share more than quadrupling and SOL per share growing over 20%, but this filing is an Item 2.02 and 9.01, which typically does not move the stock beyond 1.5% in a week as it is routine or already-priced-in news.
OUR ANALYSIS → VIEW 8-K →Ondas Inc. reported record Q3 revenue of $167.5 million, up 100% sequentially and more than 16-fold year over year, and raised its full-year 2026 revenue target to at least $550 million. The company also initiated a 2027 revenue target of at least $1.1 billion and expects operating-platform Adjusted EBITDA profitability in Q4 2026.
OUR ANALYSIS → VIEW 8-K →Leatt Corp reports a 43% increase in quarterly revenues to $20.46 million and a 309% increase in net income to $2.20 million, driven by strong sales across product categories and the recoupment of global trade tariffs, with the launch of new products and marketing campaigns contributing to the growth
OUR ANALYSIS → VIEW 8-K →CorMedix Inc. reported Q3 2026 revenue of $54.5 million, beating street consensus, and announced the acquisition of Heron Therapeutics' assets, expected to be immediately accretive to earnings and free cash flow upon closing. The company also narrowed its adjusted EBITDA guidance and suspended 2027 DefenCath revenue guidance due to CMS reimbursement framework changes.
OUR ANALYSIS → VIEW 8-K →Latch, Inc. reported an 18.1% year-over-year increase in software revenue and a gross margin expansion to 55.2%, but also incurred a $13.6 million non-cash goodwill impairment charge, leading to a net loss of $20.5 million. The company is executing a restructuring plan to reduce operating costs and accelerate its path to profitability.
OUR ANALYSIS → VIEW 8-K →ERock's Q3 revenue increased nearly 4x quarter-over-quarter, driving positive net income of $8.9MM and Adjusted EBITDA of $12.6MM, with a strong liquidity position and reaffirmed 2026 guidance
OUR ANALYSIS → VIEW 8-K →The company reported record quarterly revenues and adjusted EBITDA, with an 85% increase in revenues and a 99% increase in adjusted EBITDA from the prior year, and also announced a $150 million stock repurchase program, but this is somewhat offset by the dilutive effect of the repurchase authorization being less impactful than the earnings beat.
OUR ANALYSIS → VIEW 8-K →Twist Bioscience reported a record revenue of $459.4 million in Fiscal 2026, a 22% increase over Fiscal 2025, and provided fiscal 2027 revenue guidance of $550M-$560M, representing 21% year-over-year growth at the midpoint. The company's strong top-line revenue growth and expanded gross margin are notable positives.
OUR ANALYSIS → VIEW 8-K →The company reported a 21% year-over-year revenue growth and a 95% year-over-year increase in gross profit, with adjusted EBITDA of $5.1 million, but also has an At-The-Market (ATM) facility availability which could lead to dilution
OUR ANALYSIS → VIEW 8-K →DPC Holdings reported record third quarter 2026 revenue of $308 million, up 39% year over year, and net income of $32 million, versus a ($42) million loss in the third quarter of 2025, also upgrading full year 2026 guidance and issuing full year 2027 guidance
OUR ANALYSIS → VIEW 8-K →ADI Global Distribution Inc. reported a net loss of $655 million, including a $659 million non-cash goodwill impairment charge, and lowered its full-year outlook due to a challenging residential market and weaker-than-anticipated demand, despite a 9% year-over-year increase in net revenue to $1,306 million.
OUR ANALYSIS → VIEW 8-K →SOLV Energy reported strong Q3 2026 financial results, with revenue up 65% year over year and net income of $123 million, and also raised its full-year 2026 financial guidance. The company completed the acquisition of ASB Energy Services, expanding its self-perform high-voltage construction capabilities.
OUR ANALYSIS → VIEW 8-K →Elite Pharmaceuticals reported a 10.4% increase in revenues to $40.1 million and a 21% increase in income from operations to $9.9 million for the second quarter of fiscal year 2027, with net income attributable to common shareholders of $17.3 million. The company will host a conference call to discuss the results and provide a business update.
OUR ANALYSIS → VIEW 8-K →The company has extended the deadline for issuing senior non-voting preferred shares to December 18, 2026, as part of a financial assistance agreement, which may indicate potential dilution or covenant pressure, but the news is not quantifiably surprising or impactful enough to move the stock beyond 1.5% in a week.
OUR ANALYSIS → VIEW 8-K →The company completed an underwritten offering of Series A Common Stock and pre-funded warrants, resulting in $115 million in gross proceeds, which will be used to fund current operations through mid-2029, but this capital raise represents dilution for existing shareholders. The registrational U.S. AURORA Phase 3 clinical trial for denifanstat is underway, with topline data anticipated in the seco
OUR ANALYSIS → VIEW 8-K →Generate Biomedicines reported its Q3 financial results and provided updates on clinical programs, including progress with GB-0895 in severe asthma and COPD, and collaborations with Zealand Pharma and Anthropic, but did not disclose any quantified surprises or significant financial metrics that would indicate a substantial impact on the stock price.
OUR ANALYSIS → VIEW 8-K →The company reported a 17% decrease in revenue and a 6% decrease in net loss for the third quarter, but showed improvement in operating performance with a 25% improvement in net loss for the first nine months of 2026. Adjusted EBITDA increased by 10% for the quarter and 88% for the nine months ended September 30, 2026.
OUR ANALYSIS → VIEW 8-K →PodcastOne reports record revenue of $31.5M and adjusted EBITDA of $2.9M for the first half of fiscal 2027, with Q2 revenue increasing year-over-year to $15.4 million and adjusted EBITDA rising 27% to $1.4 million. This quantified surprise in earnings and guidance may positively impact the stock price.
OUR ANALYSIS → VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →The material filings, RNS and EU notices in one email every market day, read and scored by AI.
Subscribe free →Nov 10 (146) · Nov 9 (177) · Nov 6 (83) · Nov 5 (348) · Nov 4 (277) · Nov 3 (185) · Nov 2 (126) · Oct 30 (64) · Oct 29 (248) · Oct 28 (199) · Oct 27 (164) · Oct 26 (70) · Oct 23 (37) · Oct 22 (131) · Oct 21 (108) · Oct 20 (68) · Oct 19 (30) · Oct 16 (14) · Oct 15 (37) · Oct 14 (23)